Your session is about to expire
← Back to Search
Unknown
ADX-629 for Alcohol Intoxication
Phase 1 & 2
Waitlist Available
Research Sponsored by Aldeyra Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up in the two days of each cycle (each cycle is 2 days)
Awards & highlights
Study Summary
This trial is testing a new drug for safety and activity in people with elevated ethanol levels.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ in the two days of each cycle (each cycle is 2 days)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~in the two days of each cycle (each cycle is 2 days)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Assessment of symptoms using the Global Impression Visual Analog Scale
Secondary outcome measures
Assessment of symptoms using the Alcohol Toxicity Symptom Scale
Assessment of symptoms using the Clinical Global Impression - Impairment Severity Scale
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: ADX-629 Oral TabletsExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ADX-629
2021
Completed Phase 2
~110
Find a Location
Who is running the clinical trial?
Aldeyra Therapeutics, Inc.Lead Sponsor
29 Previous Clinical Trials
4,002 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger